Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03762772 · ClinicalTrials.gov registry record · Phase 1
Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVG
A Phase 1 study of HIV and HSV, sponsored by CONRAD.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT03762772 is a Phase 1 study of HIV and HSV that has completed, run by CONRAD. The registered enrollment target is 16 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03762772, a Phase 1 study of HIV and HSV, has completed, sponsored by CONRAD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this Phase I study is to assess the safety, pharmacokinetics, and pharmacodynamics of a combination vaginal insert containing tenofovir alafenamide (TAF) and elvitegravir (EVG). This study will be the first-in-human study for a vaginally administered TAF/EVG insert and will evaluate safety, PK and PD after a single dose. It is hypothesized that the combination insert will be safe and well-tolerated by study participants and that the insert will offer an expanded window of preventive activity and a regimen with flexibility and forgiveness.
Interventions
- DRUG TAF/EVG Vaginal Insert
Study Locations (1)
Virginia
- Clinical Research Center at Eastern Virginia Medical School (NOT RECRUITING ADDITIONAL SITES) - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-12-10 |
| Est. Completion | 2019-03-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03762772
The ClinicalTrials.gov registry entry for NCT03762772 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (96% lower). The listed sponsor is CONRAD, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which TAF/EVG Vaginal Insert is the first listed.
NCT03762772 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT03762772 about?
NCT03762772 is a clinical study titled "Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVG". The purpose of this Phase I study is to assess the safety, pharmacokinetics, and pharmacodynamics of a combination vaginal insert containing tenofovir alafenamide (TAF) and elvitegravir (EVG). This study will be the first-in-human study for a vaginally administered TAF/EVG insert and will evaluate ...
What is the current status of trial NCT03762772?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-12-10. Estimated completion is 2019-03-20.
What conditions does trial NCT03762772 study?
This clinical trial studies the following conditions: HIV, HSV.
What interventions are being tested in trial NCT03762772?
The interventions under investigation include: TAF/EVG Vaginal Insert (DRUG).
Who is sponsoring clinical trial NCT03762772?
This trial is sponsored by CONRAD, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03762772 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
RECRUITING · Phase 1
-
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
RECRUITING · Phase 1
-
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV
RECRUITING · Phase 1
-
HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)
RECRUITING · Phase 1
-
A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV
ACTIVE NOT RECRUITING · Phase 1
-
Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.